Member Info for myoung

That is a weird trade, I agree! £39.75k Is that classed as a sell or a buy? and how do you do it when you are not trading?

...To Offer FDA Cleared Virtual Colonoscopy With ColonCAD API INFINITT North America, a leading provider of image and information management technologies for healthcare, recently announced a marketing partnership with Medicsight PLC to offer an FDA-cleared, integrated ColonCAD API package within its Xelis Colon application for improved detection of abnormalities within the large intestine. CT Colonography (CTC), or virtual colonoscopy, is a low dose CT scan of the cleansed and gas-distended colon performed to detect polyps and masses. Advantages of CTC over conventional optical colonoscopy methods are that there is no sedation required, it is minimally invasive and it can be performed following an incomplete optical colonoscopy. CTC has received endorsement from the American Cancer Society among other organizations. ColonCAD API is an advanced Computer-Aided Detection (CAD) algorithm which analyzes scan data and automatically highlights specific regions of interest that are indicative of potential colorectal polyps, thus helping radiologists to identify abnormalities within the colon that may be the early precursors of potential life threatening disease. With more radiologists learning to interpret CTC exams, it is anticipated that CAD will become an integral component of CTC interpretation. The FDA clearance of ColonCAD API was supported by a large clinical trial involving 15 radiologist readers who each reviewed 112 CT colonography cases, both unassisted and assisted by ColonCAD. When assisted by ColonCAD, it was employed as a second reader to support radiologists in their evaluation after they had made an initial review of all the CTC image data. Cases were from a mixture of symptomatic and asymptomatic patients. The clinical trial results demonstrated that, when assisted by ColonCAD, radiologists' accuracy for detecting polyps of all sizes was significantly improved compared with unassisted reading. The standalone performance of ColonCAD API 3.1 was also demonstrated using a validation database of cases independent of those used to train the CAD: 92.6% sensitivity in detecting polyps = 10mm 87.6% sensitivity in detecting polyps = 5mm Colorectal cancer is the third most common cancer in men and the second in women worldwide.1 The combination of ColonCAD API - with its proven ability to increase radiologists' performance for the detection of polyps in CT colonography - and INFINITT's state-of-the-art Xelis application provides physicians with the support they need to detect this deadly disease at the earliest possible stage. so even with the bad news right now, companies are still interested in the software.

to Offer Computer Aided Detection with Supercomputing Functional Analytics Read more: http://www.sfgate.com/cgi-bin/article.cgi?f=/g/a/2011/07/12/prweb8634562.DTL#ixzz1RtHsKRek Medicsight PLC, an industry leader in the development of Computer Aided Detection (CAD) and medical image analysis software, has entered into an agreement with Ziosoft, Inc., the pioneer in supercomputing advanced visualization and functional analytics. The agreement includes the integration of Medicsight's ColonCAD™ API software and Ziosoft's Ziostation™ technology as well as distribution of both technologies by Ziosoft in the U.S. One of the first U.S. sites to use the combined Medicsight and Ziosoft technologies will be the University of Wisconsin School of Medicine and Public Health (UWH) in Madison. "The partnership between Ziosoft and Medicsight should make a compelling match for CT colonography interpretation," said Perry J. Pickhardt, professor of Radiology at UHW. "CTC will definitely benefit from the pairing of these companies which are two recognized leaders in the advanced visualization field." Medicsight received U.S. regulatory clearance for clinical use of its technology in May. Medicsight's ColonCAD is designed to assist radiologists during their review of CT colonography (CTC - also known as "Virtual Colonoscopy") images by automatically highlighting potential colorectal polyps (possible precursors to colorectal cancer) on the CT image. The regulatory clearance was supported by a large clinical trial involving 15 radiologist readers who each reviewed 112 patient CT colonography cases. The clinical trial results demonstrated that, when assisted by ColonCAD, radiologists' accuracy for detecting polyps of all sizes was significantly improved compared with unassisted reading. "Having recently received U.S. regulatory clearance for our ColonCAD software, we are now entering this important market with strategic partnerships," said Allan Rowley, CEO for Medicsight. "Ziosoft's supercomputing technology provides a powerful alliance with our own state-of-the-art software. Both companies are committed to enabling more confident diagnoses with technology that has passed the scrutiny of regulatory bodies." Ziosoft holds numerous clearances for a variety of applications for its supercomputing visualization and functional analytics technology. Medicsight and Ziosoft have been partnering in Europe prior to the U.S. clearance of ColonCAD software. "Both of our companies provide highly accurate and reproducible image visualization and functional analytics software to aid clinicians in diagnoses and treatment planning," said Rob Royea, president and COO for Ziosoft. "We look forward to bringing our collective technologies to radiologists and other healthcare providers in support of excellence in patient care."

...Potentially Misappropriated Funds MGT Capital Investments Inc. (MGT) and Medicsight PLC (MDST.LN), its majority-owned subsidiary, have launched investigations to uncover potentially misappropriated funds. Shares of both companies were halted Monday ahead of the disclosure, which didn't name any perpetrators of the alleged misappropriations. U.K.-based Medicsight provides analysis software for the medical imaging market. MGT owns about 54% of the firm, according to FactSet Research. Shares of MGT and Medicsight were down 5.8% and 18%, respectively, over the past month. The holding company said Medicsight Chief Executive Allan Rowley was suspended earlier this month pending the investigations' outcome. Medicsight Director Robert Ladd, who is also the interim chief executive of MGT, has been tapped to head the medical-imaging firm until then. Recently appointed Medicsight non-executive director Steven Harris has also resigned from the company's board. Calls to numbers listed for Medicsight and MGT's Ladd weren't immediately returned. MGT's management said it thinks the potential wrongdoing happened before Feb. 7, when the company's current board was constituted. MGT received notice last month from NYSE Amex that it had fallen out of compliance with the exchange's listing standards by dipping below the threshold for stockholders' equity. The company says it plans to regain compliance.

I'm not selling these when they come back on.

To me it sounds like the CEO might have been doing something unethical with company funds? Perhaps bribery? Who knows. Either way. The shares will recommence trading again. I am holding. Wait and see what happens.

this is the MD training at home website http://www.mdtrainingathome.com/

Surprised nobody has noticed today's RNS! ///// Medicsight enters sponsorship agreement with MD Training @home The future of physician training Medicsight PLC (AIM: MDST), an industry leader in the development of Computer-Aided Detection (CAD) and medical image analysis software is pleased to announce it has entered into an agreement to provide exclusive CAD sponsorship for all CT colonography courses provided by MD Training @home (MDT). MDT is a collection of interactive training programs focused on imaging modalities. MDT programs allow physicians to acquire training and CME accreditation using a convenient and cost-effective virtual model. The courses are designed to enhance the physician's clinical practice skills by providing online tools and remote-mentored training to interpret patient exams. ColonCAD™ API is integrated within MDT's eLearning cloud solution, and will be utilised during hands-on CT colonography tutorials. ColonCAD™ API is an advanced Computer-Aided Detection algorithm which has been cleared for marketing in the United States by the Food and Drug Administration (FDA). ColonCAD™ has been clinically proven to significantly improve radiologists' overall performance when interpreting CT colonography images. The CAD analyses scan data and automatically highlight specific regions of interest that are indicative of potential colorectal polyps, thus helping radiologists to identify abnormalities within the colon that may be the early precursors of potential life threatening disease. Allan Rowley, CEO of Medicsight, said: "Medicsight is committed to supporting and developing physician training. This partnership with MD Training @home demonstrates Medicsight's commitment to furthering clinical education and demonstrates the benefits ColonCAD™ API can provide for physicians during their interpretation of CT colonography examinations." "This further extends our commitment to the physician training market by offering the most advanced technology to our customers," states Jeff Williams, COO of MD Training @home. "In today's heavily regulated and compliance driven environment, this partnership also provides Medicsight with excellent opportunities to maximise brand exposure to all physicians who participate." /////

Annual results RNS like last years so I'm not worried. Look at the chart for last year in July and August when the interim results game out (5 Aug). I'd expect some big movement then. If I wasn't on honeymoon right now I'd be topping up!

4 days till I get married! then 7 days till the AGM! its going to be a tasty week! I'd be happy with that. tempted to buy some more and average down a little more.

Hi All List of the upcoming events 18 June 2011 3rd conference of Japan Society of Gastrointestinal CT Technical Research National Cancer Center, Tokyo, Japan Perhaps we will get the Japanese approval?! 12-16 Sept ESGAR CTC Workshop Dublin, Ireland

according to google mdst finished 1.81% up at 6.75p. looks like we have a 6-8p range currently.

Just realised it was happypig who said about 3 years for approval! I cant see the news not being anything other than positive. Sounds certain that clinicians love this product and CAD is being used alot more in procedures now. Thanks for the info on the 21 June, fingers crossed its good. I shall be away on my honeymoon then so coming back in 10 days could be interesting!

So if i've read this correctly. the marketing and sales can commence now. FDA clearance/approvals are notoriously long. I work for a medical company and some of our products have lengthly delays. some have been in approval for 5 years!

following up on this. as quoted from the FDA website. "Section 510(k) of the Food, Drug and Cosmetic Act requires device manufacturers who must register, to notify FDA of their intent to market a medical device at least 90 days in advance. This is known as Premarket Notification - also called PMN or 510(k). This allows FDA to determine whether the device is equivalent to a device already placed into one of the three classification categories. Thus, "new" devices (not in commercial distribution prior to May 28, 1976) that have not been classified can be properly identified. Specifically, medical device manufacturers are required to submit a premarket notification if they intend to introduce a device into commercial distribution for the first time or reintroduce a device that will be significantly changed or modified to the extent that its safety or effectiveness could be affected. Such change or modification could relate to the design, material, chemical composition, energy source, manufacturing process, or intended use." Anradu what do you mean about 3 more years to achieve?

Google finance shows this at 9.75p up 34%. tomorrow morning should be tasty. http://www.google.co.uk/finance?q=LON:MDST

slight retrace on the cards here. should have realised. Still with Japanese Approval (potentially) coming soon, we should see some more movement.

I'm in as well. Done alot of reading about this. when you consider they were trading at 25p a while back that should be the next target. It's all about sales now and also the application with the regulatory authorities in Japan. plenty to look forward to now.

Morning all. Just popped over from the solg board. (dead boring over there) I've had an eye on ggg for a while now. Just noticed the price target of 51p. I don't know a great deal about ggg but is this a realistic target? I've watched this stock since the 12p days and its looking good.

This company is one of the biggest veterinary groups in the Country. They are very strong I would say. Looks like an over reaction. 4-5 years ago this stock was over double what it is now!